Trial reportNature medicine2018
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
3 registry-linked trialsAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 474 papers, 13 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
474citing papers in PubMed, 13 pooled it
32.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single Center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of Neoadjuvant and Adjuvant Pembrolizumab on Top of Standard Chemo-Radiotherapy (Stupp Protocol) in Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme (GBM).
A Randomized Phase II Study of Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients: ESCALATE Study
Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Who cites it
474 citing papers in PubMed, 13 syntheses or guidelines pooled it, 843 citations in OpenAlex.
- Sex, Timing, and Outcomes of Curative-Intent Immunotherapy: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- Pooled it
- Immuno-oncology in the perioperative setting: the next frontier in resectable head and neck cancers - a systematic review.BMC cancer · 2026Pooled it
- Impact of immune checkpoint inhibitors as neoadjuvant/perioperative therapy for locally advanced resectable gastric/gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Efficacy and safety of neoadjuvant chemotherapy with immunotherapy versus chemotherapy alone in esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis.The oncologist · 2025Pooled it
- Efficacy of PD-1/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis.Future oncology (London, England) · 2025Pooled it
- Efficacy of Immune Checkpoint Inhibitors in the Treatment for Head and Neck Cancer Patients: A Systematic Review and Network Meta-Analysis.Oncology research · 2025Pooled it
- A comprehensive review and case series of adjuvant and neoadjuvant therapies in acral melanoma with emerging insights from CT DNA testing.Frontiers in oncology · 2025Pooled it
- Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.JAMA network open · 2024Pooled it
- Evaluating the efficacy and safety of different neoadjuvant immunotherapy combinations in locally advanced HNSCC: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.Journal for immunotherapy of cancer · 2023Guideline
- Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2023Pooled it
- Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial.Journal of gynecologic oncology · 2026Trial
- Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study.Journal for immunotherapy of cancer · 2026Trial
- [European journal of nuclear medicine and molecular imaging · 2026Trial
- Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.Nature medicine · 2026Trial
- Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.Nature cancer · 2026Trial
- Trial
- Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
414 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 4 institutions in 2 countries.
Christian U BlankMedical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl.
Elisa A RozemanMedical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lorenzo F FanchiDivision of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Karolina SikorskaDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Bart van de WielDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pia KvistborgDivision of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Oscar KrijgsmanDivision of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Marlous van den BraberDivision of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Daisy PhilipsDivision of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Annegien BroeksDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Johannes V van ThienenMedical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Henk A MalloMedical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Sandra AdriaanszMedical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Sylvia Ter MeulenSurgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Loes M PronkDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lindsay G Grijpink-OngeringDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Annemarie BruiningDepartment of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Rachel M GittelmanAdaptive Biotechnologies, Seattle, WA, USA.
Sarah WarrenNanoString Technologies, Inc., Seattle, WA, USA.
Harm van TinterenDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Daniel S PeeperDivision of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
John B A G HaanenMedical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Alexander C J van AkkooiSurgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ton N SchumacherDivision of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. t.schumacher@nki.nl.
The Netherlands Cancer Institute · NLAdaptive Biotechnologies (United States) · USNanostring Technologies (United States) · USOncode Institute · NL
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free survival of stage III melanoma patients
Indexed as
AdultAgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCTLA-4 AntigenDisease-Free SurvivalHumansIpilimumabMaleMelanomaMiddle AgedNeoadjuvant TherapyNeoplasm StagingNivolumabAntibodies, MonoclonalCTLA-4 AntigenCTLA4 protein, humanIpilimumabNivolumab
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.